Compare Moderna, Inc. (MRNA) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Plug Power Inc — how do they compare? Moderna, Inc. trades at $196.72 (market cap $78.44B), while Plug Power Inc trades at $1.75 (market cap $2.49B). The key difference: Moderna, Inc. is far larger — about 31.5× Plug Power Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Plug Power Inc for 41 Days on average.
| MRNA | PLUG | |
|---|---|---|
Market Cap | $78.44B | $2.49B |
Volume | 14,597,511 | 47,846,349 |
Sector | Health | Industrials |
52-Week High | $203.46 | $4.14 |
52-Week Low | $22.36 | $1.73 |
Typical Hold Time | 59 Days | 41 Days |
Enterprise Value | $74.59B | $3.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Plug Power (PLUG) trades at $1.73, down 6.99% today, with a bearish technical signal and negative earnings momentum. The company continues to report significant losses with a -220.59% net income margin and negative cash flow, though recent electrolyzer supply agreements and international expansion provide some operational catalysts. Analyst sentiment is mixed with 44.73% buy ratings but a consensus price target of $3.13 suggesting 81% upside potential from current levels.
The stock faces substantial fundamental challenges with persistent losses and negative cash flow, but maintains analyst support due to its positioning in the growing green hydrogen market. Key risks include execution challenges in achieving profitability, high cash burn requiring continued financing, and competitive pressures in the clean energy sector. The current price near the analyst low target of $1.65 indicates limited downside protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
